Article
Interaction between p53 mutation and a somatic HDMX biomarker better defines metastatic potential in breast cancer.
Cancer research - 15 Feb 2015
Grawenda Anna M, Møller Elen K, Lam Suzanne, Repapi Emmanouela, Teunisse Amina F A S, Alnæs Grethe I G, Børresen-Dale Anne-Lise, Kristensen Vessela N, Goding Colin R, Jochemsen Aart G, Edvardsen Hege, Bond Gareth L
Abstract excerpt
TP53 gene mutation is associated with poor prognosis in breast cancer, but additional biomarkers that can further refine the impact of the p53 pathway are needed to achieve clinical utility. In this study, we evaluated a role for the HDMX-S/FL ratio as one such biomarker, based on its association with other suppressor mutations that confer worse prognosis in sarcomas, another type of cancer that is surveilled by...
Read the complete abstract on PubMedTopics
Share this publication in a Topic to start or enrich a Post.